Ionis Pharmaceuticals (IONS)
(Real Time Quote from BATS)
$47.71 USD
+0.65 (1.38%)
Updated Aug 13, 2024 10:00 AM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Price, Consensus and EPS Surprise
IONS 47.71 +0.65(1.38%)
Will IONS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for IONS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for IONS
The Zacks Analyst Blog AstraZeneca, Ionis and Sanofi
How Should You Play AstraZeneca (ABBV) After Q2 Beat, View Raise?
IONS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ionis (IONS) Q2 Earnings and Revenues Beat, Stock Rises
Ionis Pharmaceuticals (IONS) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Ionis Pharmaceuticals (IONS) Reports Q2 Loss, Tops Revenue Estimates
Other News for IONS
Tweedy Browne Amplifies Stake in CNH Industrial NV by Over 1300%
Ionis Pharmaceuticals: Harnessing RNA-Targeted Therapies For Long-Term Shareholder Value
ClearBridge All Cap Growth Strategy Q2 2024 Commentary
Insider Sale at Ionis Pharmaceuticals Inc (IONS) by EVP, Chief Development Officer Richard Geary
Canaccord reiterates Buy rating on Clene following 'intriguing' new data